Main Article Content

Maria Ulfa
Krisna Murti

Future research will continue to be carried out in terms of looking for molecular markers involved in the early processes of carcinogenesis, metastasis and therapeutic targets in prostate cancer patients. MicroRNAs (miRNAs) are small noncoding RNAs that contribute to prostate cancer progression by controlling genes involved in the androgen receptor (AR) signaling pathway, ectopic expression of proteins involved in the cell cycle and apoptosis, epithelial-mesenchymal transition (EMT) and metastasis of cancer stem cells (CSCs). This study was an exploratory study, the aim was to assess miRNA expression in low histopathological grade prostate cancer compared with high histopathological grade prostate cancer. The novelty of this research is to assess the 25 most increased (up-regulated) and 25 lowest (down-regulated) miRNAs from 800 types of miRNA. Next, we will analyze the mechanisms and confirm the carcinogenesis of prostate cancer. The research results can be used for further research data, especially for targeted therapy in prostate cancer patients.

Keywords: carcinogenesis miRNA up-regulation down-regulation prostate cancer
Kench JG, Amin MB, Berney DM, Compérat EM, Cree IA, Gill AJ, et al. WHO. Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. Histopathology. 2022 Oct 2;81(4):447–58.
Kiełb P, Kowalczyk K, Gurwin A, Nowak Ł, Krajewski W, Sosnowski R, et al. Novel Histopathological Biomarkers in Prostate Cancer: Implications and Perspectives. Biomedicines. 2023 May 26;11(6):1552.
Rafikova G, Gilyazova I, Enikeeva K, Pavlov V, Kzhyshkowska J. Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers. Int J Mol Sci. 2023 Aug 14;24(16):12797.
Doldi V, El Bezawy R, Zaffaroni N. MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers (Basel). 2021 May 14;13(10):2380.
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020 Aug 16;20(8):455–69.
Grypari IM, Tzelepi V, Gyftopoulos K. DNA Damage Repair Pathways in Prostate Cancer: A Narrative Review of Molecular Mechanisms, Emerging Biomarkers and Therapeutic Targets in Precision Oncology. Int J Mol Sci. 2023 Jul 13;24(14):11418.
Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanisms of androgen-independent prostate cancer. EJIFCC. 2014;25(1):42.
Saraon P DAJKDE. Mechanism of androgens-independent prostate cancer. The Journal of The International Federation of Clinical Chemistry and Laboratory Medicine. 2014;25(1):42.
Sekhon K, Bucay N, Majid S, Dahiya R, Saini S. MicroRNAs and epithelial-mesenchymal transition in prostate cancer. Oncotarget. 2016 Oct 11;7(41):67597–611.
Borga C, Meeran SM, Fassan M. Non-coding RNAs, a real Next-Gen Class of Biomarkers? Noncoding RNA Res. 2019 Sep;4(3):80–1.
Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2021 Jan;1875(1):188491.
Stafford MYC, McKenna DJ. MiR-182 Is Upregulated in Prostate Cancer and Contributes to Tumor Progression by Targeting MITF. Int J Mol Sci. 2023 Jan 17;24(3):1824.
Bilal M, Javaid A, Amjad F, Youssif TA, Afzal S. An overview of prostate cancer (PCa) diagnosis: Potential role of miRNAs. Transl Oncol. 2022 Dec;26:101542.